PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.65%
Both companies show declining cash positions (-7.65% vs TRAW's -24.19%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.65%
Below half of TRAW's -24.19%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.05%
Other current assets growth < half of TRAW's -33.98%. David Dodd sees a leaner approach to short-term items.
-5.46%
Below half of TRAW's -23.11%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
13.35%
Below half TRAW's -55.00%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.05%
Less than half of TRAW's 1141.67%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
2.60%
Below half of TRAW's 393.75%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-5.18%
Below half of TRAW's -22.53%. Michael Burry sees a potential red flag for stagnation or capital shortage.
41.04%
Less than half of TRAW's -5.28%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.09%
Above 1.5x TRAW's 2.81%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.41%
Above 1.5x TRAW's 2.12%. Michael Burry sees a potential leverage warning sign.
4.74%
Higher Common Stock (Book Value) Growth compared to TRAW's zero value, indicating worse performance.
-3.50%
≥ 1.5x TRAW's -1.50%. David Dodd sees higher yoy retained profits than competitor.
-4.99%
Less than half of TRAW's -71.43%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-23.90%
Below half TRAW's -50.40%. Michael Burry sees potential underperformance in building shareholder capital.
-5.18%
Below half TRAW's -22.53%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.42%
Less than half of TRAW's 24.19%. David Dodd sees better deleveraging or stronger cash buildup than competitor.